Clinical Trials List
2022-05-20 - 2026-12-31
Phase III
Recruiting3
ICD-10C67.9
Malignant neoplasm of bladder, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9188.9
Malignant neoplasm of bladder, part unspecified
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Wei-Ching Lin 無
- Chao-Hsiang Chang 無
- Po-Jen Hsiao 無
- Su-Peng Yeh 無
- Po-Fan Hsieh 無
- Yu-De Wang 無
- Ching-Chan Lin 無
- 鄭富銘 無
- Chi-Ping Huang 無
- 陳冠亨 無
- 蔡禮賢 無
- Che-Hung Lin 無
- Han Chang 無
- Chi-Rei Yang Division of Urology
- Yi-Huei Chang 無
- 賴俊佑 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Hsiao-Jen Chung Division of Urology
- 陳威任 Division of Urology
- Yu-Hua Fan Division of Urology
- 潘競成 Division of Others
- William Huang Division of Urology
- Tzu-Hao Huang Division of Urology
- Ming-Hsuan Ku Division of Urology
- 柯玉潔 Division of Ophthalmology
- Yen-Hwa Chang Division of Urology
- Tzu-chun Wei Division of Urology
- Tzu-Hsiang Hsu Division of Urology
- Tzu-Ping Lin Division of Urology
- Chih-Chieh Lin Division of Urology
- Jia-An Hong Division of Radiology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 陳彥達 Division of Urology
- 陳建旭 Division of Urology
- 張殷綸 Division of Urology
- 吳宗憲 Division of Urology
- 康智雄 Division of Urology
- 沈元琦 Division of Urology
- 陳柏諺 Division of Urology
- 宋明澤 Division of Others
- 鄭元佐 Division of Urology
- 柳易揚 Division of Urology
- 吳彥廷 Division of Urology
- 何仁文 Division of Ophthalmology
- 王弘仁 Division of Urology
- YAO-CHI CHUANG Division of Urology
- 劉惠瑛 Division of Urology
- 蔡佳宏 Division of Urology
- 湯禹舜 Division of Radiology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
6 participants
-
Global
784 participants
